Gene therapy could revolutionize retinal disease treatment, promising consistent dosing, fewer injections, and improved patient outcomes, as highlighted by expert Christina Y. Weng.
Christina Y. Weng, MD, MBA
Advertisement
Christina Y. Weng, MD, MBA, is a professor and the Alice R. McPherson Retina Research Foundation Chair in Ophthalmology at Baylor College of Medicine.
Articles by Christina Y. Weng, MD, MBA
Christina Y. Weng, MD, breaks down emerging gene therapy programs poised to change how retina specialists treat chronic eye disease.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
REMAIN-1: Improved GLP-1-Induced Weight Loss Retention With Revita DMR System
2
SYMPHONY-PE: Early Thrombectomy Improves Pulmonary Embolism Outcomes
3
AXIOMATIC-TKR: Milvexian Decouples Thrombosis, Hemostasis in DVT
4
FDA Grants Obinutuzumab Priority Review as Primary Membranous Nephropathy’s Potential First Therapy
5